Skip to main content

Table 3 Comparison of patient characteristics between those with and without acute exacerbation of interstitial pneumonia (IP)

From: Characteristics of non-small-cell lung cancer with interstitial pneumonia: variation in cancer location, histopathology, and frequency of postoperative acute exacerbations in interstitial pneumonia

 

Characteristic

Without postoperative AE of IP (n = 112)

With postoperative AE of IP (n = 8)

P

Age, years

 

74.5 (50–90)

71.5 (60–85)

N.S.

Sex

Male

91

6

 

Female

21

2

N.S.

Smoking status

Never

7

0

 

Current or former

105

8

N.S.

Brinkman Index

 

900 (0–4400)

850 (200–2380)

N.S.

HRCT IP pattern

UIP

52

6

 

Non-UIP

60

2

N.S.

Pulmonary emphysema

Yes

85

7

 

No

27

1

N.S.

Treatment agents for preexisting IP

Steroids

5

0

N.S.

Antifibrotic agents

1

0

N.S.

Pulmonary function test results

VC (mL)

3290 (1680–5790)

3025 (1920–3910)

N.S.

% predicted VC

100.0 (55–151)

88.0 (82–106)

0.044

FVC (mL)

3290 (1560–5790)

2970 (1920–3910)

N.S.

% predicted FVC

102.1 (56–162)

92.0 (86–114)

N.S.

% predicted FEV1.0

69.9 (41.5–93.1)

77.6 (55.3–82.4)

N.S.

% predicted DLco

74.0 (17–133)

63.0 (48–116)

N.S.

Laboratory data

KL-6 (U/mL)

487.0 (163–5051)

599.0 (233–1386)

N.S.

SP-D (ng/mL)

109.0 (21.0–542.0)

156.0 (62.1–530.0)

N.S.

SP-A (ng/mL)

49.8 (17.4–291.6)

67.3 (26.9–143.0)

N.S.

GAP index*

 

3 (0–6)

2.5 (1–4)

N.S.

Surgical procedure

Lobectomy

75

8

0.047

Segmentectomy

23

0

N.S.

Wedge resection

14

0

N.S.

  1. Data are presented as number or median (range)
  2. IP interstitial pneumonia, HRCT high-resolution computed tomography, UIP usual interstitial pneumonia, VC vital capacity, FVC forced vital capacity, FEV1.0 forced expiratory volume in one second, DLCO diffusing capacity for carbon monoxide, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D, SP-A surfactant protein A, GAP Gender–Age–Physiology, N.S. not significant
  3. * The GAP index was calculated using a multidimensional index and staging system for idiopathic pulmonary fibrosis [28]